Immuno-Grade GPR6 Receptor Antibodies

GPR6 (G Protein-Coupled Receptor 6) is an orphan GPCR that exhibits constitutive activity, primarily coupling to the Gs protein to increase intracellular cAMP levels. It shares structural similarity with cannabinoid receptors and is part of the MECA (melanocortin, endothelial differentiation gene, cannabinoid, adenosine) receptor cluster. GPR6 is predominantly expressed in the central nervous system, with particularly high levels in the striatum and other brain regions involved in motor control and cognitive function. It is also found at lower levels in peripheral tissues, though its functional roles outside the brain are less well understood. GPR6 is considered a potential pharmacological target, especially in the context of neurodegenerative and neuropsychiatric disorders. It has been implicated in Parkinson’s disease and Huntington’s disease due to its role in modulating dopaminergic signaling and neuronal activity. Several synthetic inverse agonists of GPR6 have shown promise in preclinical models, making it a subject of growing interest in drug discovery, particularly for movement disorders. For more information on GPR6 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.